ONCOLOGY Vol 37, Issue 10

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma

ByLudovic Saba, MD,Kevin S. Landau, MD,Silvia Bunting, MD,Chakra P. Chaulagain, MD

October 17th 2023

Investigators discussed the potential link between secondary pure red cell aplasia and subcutaneous daratumumab/hyaluronidase formulation for multiple myeloma.

Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman

BySamia Asif, MBBS,Brendan J. Hurley, MD,Sehr Haroon, MD,Subodh Lele, MD,Bhavina Sharma MD

October 12th 2023

A young woman presents with painless lumps to the emergency department and is later diagnosed with clear cell carcinoma.

Multidisciplinary Team Approach Is Integral to Oncology Care

ByJulie M. Vose, MD, MBA

October 11th 2023

Julie M. Vose, MD, MBA, discussed why the need for multidisciplinary care is so pertinent, and how it must continue even after treatment ends.

ONCOLOGY Vol 37, Issue 10

Secondary Pure Red Cell Aplasia During Daratumumab/ Hyaluronidase Therapy for Multiple Myeloma

Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman

Multidisciplinary Team Approach Is Integral to Oncology Care

Trending on CancerNetwork

ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice

Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology

FDA Approves Revumenib in R/R NPM1-Mutant AML

ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC